Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 6Thoracic 2Gynecologic 2Gastrointestinal 2Breast 2Plasma cell 1Myeloid 1Head & Neck 1

Conditions

Microsatellite Stable Colorectal Carcinoma 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × cc-486 × Gynecologic × Clear all
NCT02900560 2022-06-10

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

Translational Research in Oncology

Phase 2 Terminated
34 enrolled 15 charts
Gynecologic

Carcinoma, Ovarian Epithelial

NCT02811497 2021-04-01

METADUR

University Health Network, Toronto

Phase 2 Completed
28 enrolled
BreastGastrointestinalGynecologic

Microsatellite Stable Colorectal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡